MannKind (MNKD) Misses Q3 EPS by 1c

Go back to MannKind (MNKD) Misses Q3 EPS by 1c

Piper Jaffray Maintains Underweight on MannKind (MNKD) Following Results and Grim Outlook

November 10, 2015 7:01 AM EST

Piper Jaffray analyst Joshua Schimmer reiterated an Underweight rating and $1.50 price target on MannKind (NASDAQ: MNKD) following results.

Schimmer commented, "While cost-cutting measures will help curtail the cash burn, the disappointing launch of Afrezza and increasing net-debt position seem to be making the... More

Leerink Partners' Ominous Sign on MannKind (MNKD)

November 9, 2015 11:29 AM EST

In addition to poor earnings, MannKind (NASDAQ: MNKD) investors are reacting to the ominous sign from Leerink Partners' Sanofi (NYSE: SNY) analyst Seamus Fernandez.

Fernandez removed Afrezza estimates from their Sanofi 2016 model and... More

MannKind (MNKD) Mentioned Cautiously on Twitter

November 9, 2015 11:26 AM EST

MannKind (NASDAQ: MNKD) was mentioned cautiously on Twitter by theStreet columnist Adam Feuerstein.

. @shaneblackmon $MNKD has to address the bankruptcy question on tonights call. Theyre very close to insolvency. How will co. survive?

Adam Feuerstein (@adamfeuerstein) November 9, 2015


... More